Pharmacokinetics and Tolerability of Telavancin at Differing Dosing Regimens in Cystic Fibrosis Adults Admitted With Acute Pulmonary Exacerbations
Phase of Trial: Phase IV
Latest Information Update: 25 May 2018
At a glance
- Drugs Telavancin (Primary)
- Indications Cystic fibrosis
- Focus Pharmacokinetics
- 27 Apr 2018 Planned End Date changed from 30 Jun 2018 to 30 Jun 2019.
- 27 Apr 2018 Planned primary completion date changed from 30 Mar 2018 to 30 Mar 2019.
- 08 Aug 2017 Status changed from not yet recruiting to recruiting.